Health Discovery Corporation (OTCBB: HDVY) announced today that the Company has been listed among the “Best & Brightest” qualifying small cap companies by MDB Capital Group LLC. According to MDB Capital Group, the Bright Lights Conference will showcase the untold IP stories of 50 public companies ranking in the 90th percentile for technology leadership from over 1,600 small cap companies with U.S. patents granted, as rated by PatentVest, MDB's proprietary IP business intelligence database. The 1st Annual Bright Lights Conference will be held on May 10 - 12, 2010 at the Palace Hotel in San Francisco. Institutional investors from several countries, as well as IP thought leaders, will be in attendance for the first public company conference to focus exclusively on selected companies with disruptive and market changing Intellectual property. “We are honored to have been selected by MDB Capital Group as one of the top companies from more than 1,600 small cap companies scored, ranked and analyzed on the basis of the rate of innovative change, as well as, the novelty, quality and industry impact of our patents," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “This recognition confirms what we have known for years, that HDC's valuable SVM technology and robust patent portfolio gives our Company a major market advantage,” said Dr. Barnhill. Health Discovery Corporation is also pleased to announce that it has expanded its already strong IP portfolio (41 issued patents and 33 pending patents) by filing new patent applications covering its recently announced mobile phone application for melanoma screening and the broad use of SVMs for analysis of spectral data, as well as filing for additional international protection for the four-gene prostate cancer test and analysis algorithm that the Company has licensed to Quest Diagnostics, Abbott Laboratories and Clarient. MDB Capital Group LLC is an institutional research and investment banking firm that focuses exclusively on companies that possess market changing, disruptive intellectual property.
About Health Discovery CorporationHealth Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings. All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.